ArticleThe oncologist2026
Conversion-intent PD-1-based chemoimmunotherapy restores surgical feasibility in borderline resectable or unresectable non-head-and-neck cutaneous squamous cell carcinoma.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe perioperative role of systemic therapy remains poorly defined in borderline resectable or unresectable non-head-and-neck locally advanced cutaneous squamous cell carcinoma (cSCC). We evaluated whether conversion-intent PD-1-based chemoimmunotherapy could restore surgical feasibility in this setting.
methodsThis single-center retrospective cohort study included consecutive patients with non-head-and-neck locally advanced cSCC treated with conversion-intent PD-1 inhibitor plus taxane/platinum-based chemotherapy between January 2022 and December 2025. The primary endpoint was conversion to surgical candidacy. Secondary endpoints included surgery, R0 resection, radiologic and pathologic responses, safety, and survival outcomes.
resultsAmong the 28 included patients, 17 (60.7%) had unresectable disease at baseline. Following conversion-intent systemic therapy, 23 patients (82.1%) were considered eligible for surgery, and 22 (78.6%) underwent curative-intent surgery. R0 resection was achieved in 16 patients overall (57.1%) and in 72.7% of patients who underwent surgery. The objective response rate was 50.0%, the disease control rate was 89.3%, and the radiologic downstaging rate was 46.4%. Primary-site pathological complete response was observed in 18.2% of patients who underwent surgery. Treatment-related adverse events were common (85.7%), whereas grade ≥3 events were infrequent (14.3%), and permanent discontinuation and surgery delay each affected only a small minority of patients.
conclusionConversion-intent PD-1-based chemoimmunotherapy was associated with restoration of surgical feasibility in selected patients with borderline resectable or unresectable non-head-and-neck locally advanced cSCC. These findings support a conversion-oriented treatment approach and suggest that surgery-related endpoints may be more informative than radiologic response alone in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.